BIOXYTRAN, INC (74)
Browse by Contract Category
Contracts
-
Modification/Amendment to Officers Employment Contract, dated October 28, 2022
(Filed With SEC on November 14, 2022)
-
Form of Subscription Agreement
(Filed With SEC on August 17, 2022)
-
Official USPTO Notice of Publication under 12(A) for the Trademark ProLectin
(Filed With SEC on June 10, 2022)
-
Approval of International Patent WO2022/099061 - Polysaccharides for IV Administration that Treat SARS-CoV-2 Infections, dated May 12, 2022
(Filed With SEC on June 10, 2022)
-
Approval of International Patent WO2022/099052 - Polysaccharides for Use in Treating Sars-Cov-2 Infections, dated May 12, 2022
(Filed With SEC on June 10, 2022)
-
Joint Venture Agreement between Bioxytran and Pharmalectin Partners, LLC, dated November 15, 2020
(Filed With SEC on April 9, 2021)
-
Form of Note Purchase Agreement, dated January 5, 2022
(Filed With SEC on January 14, 2022)
-
Form of Convertible Note, dated January 5, 2022
(Filed With SEC on January 14, 2022)
-
Form of Private Placement Memorandum dated September 17, 2021
(Filed With SEC on November 17, 2021)
-
Form of Private Placement Memorandum dated February 26, 2021
(Filed With SEC on November 17, 2021)
-
Form of Subsidiary Option dated June 4, 2021
(Filed With SEC on November 17, 2021)
-
Form of Warrant dated June 4, 2021
(Filed With SEC on November 17, 2021)
-
2017 Employee, Director and Consultant Stock Plan (Subsidiary), adopted by the Board of Directors on October 5, 2017
(Filed With SEC on June 24, 2021)
-
2021 Employee, Director and Consultant Stock Plan, adopted by the Board of Directors on January 19, 2021
(Filed With SEC on June 24, 2021)
-
License Agreement between Pharmalectin, Inc. and NDPD Pharma, Inc. dated May 2, 2021
(Filed With SEC on June 24, 2021)
-
License Agreement between Bioxytran, Inc. and Pharmalectin, Inc. dated May 5, 2020
(Filed With SEC on June 24, 2021)
-
Form of Convertible Note Agreement between Note Holders and Bioxytran, Inc., dated May 2 and 3, 2021
(Filed With SEC on June 7, 2021)
-
Form of Employment Agreement of Mike Sheikh, dated May 1, 2020
(Filed With SEC on April 9, 2021)
-
8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $64,900 dated March 18, 2020
(Filed With SEC on March 26, 2020)
-
Securities Purchase Agreement between Power Up Lending Group LLC and Bioxytran, Inc., dated March 18, 2020
(Filed With SEC on March 26, 2020)
-
Amendment #1 to Securities Purchase Agreement between Auctus Fund LLC and Bioxytran, Inc., dated February 25, 2019
(Filed With SEC on March 12, 2020)
-
Amendment #1 to Securities Purchase Agreement between Auctus Fund LLC and Bioxytran, Inc., dated October 24, 2018
(Filed With SEC on March 12, 2020)
-
Securities Purchase Agreement between Crown Bridge Partners, LLC and Bioxytran, Inc., dated October 30, 2019
(Filed With SEC on February 26, 2020)
-
Securities Purchase Agreement between Power Up Lending Group LLC and Bioxytran, Inc., dated January 18, 2020
(Filed With SEC on February 26, 2020)
-
8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $56,600 dated January 18, 2020
(Filed With SEC on February 26, 2020)
-
4% Convertible Note of Bioxytran, Inc. to Crown Bridge Partners, LLC in the Principal Amount of $55,000 dated October 30, 2019
(Filed With SEC on February 26, 2020)
-
Warrant to Purchase 22,000 shares of Common Stock of Bioxytran
(Filed With SEC on February 26, 2020)
-
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran
(Filed With SEC on January 15, 2020)
-
4% Convertible Note of Bioxytran, Inc. to EMA Financial LLC. in the Principal Amount of $125,000 dated January 10, 2020
(Filed With SEC on January 15, 2020)
-
Securities Purchase Agreement between EMA Financial LLC and Bioxytran, Inc., dated January 10, 2020
(Filed With SEC on January 15, 2020)
-
8% Convertible Note of Bioxytran, Inc. to Power Up Lending Group in the Principal Amount of $54,600 dated December 30, 2019
(Filed With SEC on January 6, 2020)
-
Securities Purchase Agreement between Power Up Lending Group and Bioxytran, Inc., dated December 30, 2019
(Filed With SEC on January 6, 2020)
-
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran
(Filed With SEC on November 25, 2019)
-
4% Convertible Note of Bioxytran, Inc. to FirstFire Global Opportunities Fund, LLC. in the Principal Amount of $125,000 dated November 20, 2019
(Filed With SEC on November 25, 2019)
-
Securities Purchase Agreement between FirstFire Global Opportunities Fund, LLC and Bioxytran, Inc., dated November 20, 2019
(Filed With SEC on November 25, 2019)
-
Form of Letter Agreement between FON Consulting, LLC and Bioxytran, Inc. dated November 11, 2019
(Filed With SEC on November 12, 2019)
-
Form of Warrant to Purchase 50,000 shares of Common Stock of Bioxytran
(Filed With SEC on November 12, 2019)
-
Form of Securities Purchase Agreement between GS Capital Partners, LLC and Bioxytran, Inc., dated No ember 7, 2019
(Filed With SEC on November 12, 2019)
-
Form of 4% Convertible Note of Bioxytran, Inc. to GS Capital Partners, LLC. in the Principal Amount of $125,000 dated November 7, 2019
(Filed With SEC on November 12, 2019)
-
8% Convertible Note of Bioxytran, Inc. to Tangiers Global, LLC in the Principal Amount of $106,300 dated October 23, 2019
(Filed With SEC on November 5, 2019)
-
Securities Purchase Agreement between Peak One Opportunity Fund, L.P. and Bioxytran, Inc., dated October 22, 2019
(Filed With SEC on November 5, 2019)
-
8% Convertible Note of Bioxytran, Inc. to PowerUp Lending Group Ltd. in the Principal Amount of $106,000 dated October 21, 2019
(Filed With SEC on November 5, 2019)
-
Securities Purchase Agreement between PowerUp Lending Group Ltd. and Bioxytran, Inc., dated October 21, 2019
(Filed With SEC on November 5, 2019)
-
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran
(Filed With SEC on November 5, 2019)
-
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran
(Filed With SEC on November 5, 2019)
-
Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019
(Filed With SEC on November 5, 2019)
-
8% Convertible Note of Bioxytran, Inc. to PowerUp Lending Group Ltd. in the Principal Amount of $106,000 dated October 21, 2019
(Filed With SEC on October 28, 2019)
-
Securities Purchase Agreement between PowerUp Lending Group Ltd. and Bioxytran, Inc., dated October 21, 2019
(Filed With SEC on October 28, 2019)
-
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran
(Filed With SEC on October 28, 2019)
-
8% Convertible Note of Bioxytran, Inc. to Tangiers Global, LLC in the Principal Amount of $106,300 dated October 23, 2019
(Filed With SEC on October 28, 2019)
-
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran
(Filed With SEC on October 28, 2019)
-
8% Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019
(Filed With SEC on October 28, 2019)
-
Securities Purchase Agreement between Peak One Opportunity Fund, L.P. and Bioxytran, Inc., dated October 22, 2019
(Filed With SEC on October 28, 2019)
-
Form of Advisory Board Agreement between Bioxytran, Inc. and Jonathan Jensen Dated September 13, 2019
(Filed With SEC on September 13, 2019)
-
Form of Advisory Board Agreement between Bioxytran, Inc. and Patrick Huddie dated September 13, 2019
(Filed With SEC on September 13, 2019)
-
Form of Advisory Board Agreement between Bioxytran, Inc. and Cynthia Tsai effective July 16, 2019
(Filed With SEC on August 1, 2019)
-
Form of Advisory Board Agreement between Bioxytran, Inc. and Jonathan Barkman effective July 15, 2019
(Filed With SEC on August 1, 2019)
-
Form of Advisory Board Agreement between Bioxytran, Inc. and Steven Aust dated June 11, 2019
(Filed With SEC on June 12, 2019)
-
Scientific Advisory Board Agreement between Bioxytran, Inc. and Asclepius LLC dated May 1, 2019
(Filed With SEC on May 6, 2019)
-
Investor Relations Agreement between Bioxytran, Inc. and Resources Unlimited NW LLC. dated April 22, 2019
(Filed With SEC on April 26, 2019)
-
License Agreement between Bioxytran, Inc. and MDX Lifesciences, Inc. dated April 4, 2019
(Filed With SEC on April 5, 2019)
-
Form of Securities Purchase Agreement between U.S. Rare Earth Minerals, Inc. and Auctus Fund, LLC, dated February 25, 2019
(Filed With SEC on March 1, 2019)
-
Form of Warrant of dated February 25, 2019
(Filed With SEC on March 1, 2019)
-
Form of Registration Rights Agreement between U.S. Rare Earth Minerals, Inc. and Auctus Fund, LLC, dated February 25, 2019
(Filed With SEC on March 1, 2019)
-
Form of Security Agreement dated February 25, 2019, between U.S. Rare Earth Minerals, Inc., and Auctus Fund, LLC, dated February 25, 2019
(Filed With SEC on March 1, 2019)
-
Form of $250,000 Senior Secured Promissory Note, dated February 25, 2019, of U.S. Rare Earth Minerals, Inc. and Auctus Fund, LLC, dated February 25, 2019
(Filed With SEC on March 1, 2019)
-
Form of Common Stock Certificate
(Filed With SEC on February 1, 2019)
-
Form of Employment Agreement of David Platt
(Filed With SEC on February 1, 2019)
-
Form of Employment Agreement of Ola Soderquist
(Filed With SEC on February 1, 2019)
-
Form of Public Offering Subscription Agreement
(Filed With SEC on February 1, 2019)
-
Form of Public Offering Subscription Agreement
(Filed With SEC on January 30, 2019)
-
Form of Employment Agreement of Ola Soderquist
(Filed With SEC on January 30, 2019)
-
Form of Employment Agreement of David Platt
(Filed With SEC on January 30, 2019)
-
Form of Common Stock Certificate
(Filed With SEC on January 30, 2019)